Pay in 4 interest-free payments of $5.00 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Proper licensing is non-negotiable
Copay amounts for weight loss treatment and GLP-1 medications with Anthem Blue Cross Blue Shield vary based on your specific plan, deductible status, and formulary tier
4 This evidence supported the MHRAs decision to extend Wegovys licence in July 2024 to include reducing the risk of serious heart events in adults living with overweight or obesity and established cardiovascular disease
As Bayer previously highlighted in their topline data announcement, the FINEARTS trial met its primary endpoint, with use of finerenone associated with a statistically significant 16% relative reduction in rate of primary outcome events compared with placebo therapy (rate ratio [RR], 0.84
US$ 20.68
US$ 22.37
US$ 20.77
US$ 24.30
US$ 29.23
